Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook 2016     Display Documents



ID: 723935.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook 2016
Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension
Authors:Richter, M. J.; Ghofrani, H. A.; Voswinckel, R.; Seeger, W.; Schulz, R.; Reichenberger, F.; Gall, H.
Date of Publication (YYYY-MM-DD):2015-03
Title of Journal:Pulm Circ
Volume:5
Issue / Number:1
Start Page:162
End Page:170
Audience:Not Specified
Abstract / Description:Inhaled iloprost has proven to be an effective therapy in patients with pulmonary hypertension (PH). However, the acute hemodynamic effect of nebulized iloprost delivered via the I-neb Adaptive Aerosol Delivery (AAD) system remains unclear and needs to be assessed. In this study, 126 patients with PH were classified according to current guidelines (59, 34, 29, and 4 patients in groups 1/1', 3, 4, and 5, respectively; 20 patients had idiopathic pulmonary arterial hypertension [iPAH]), were randomly assigned to inhale iloprost 2.5 [Formula: see text]g (n = 67) or 5.0 [Formula: see text]g (n = 59) via the I-neb AAD system, and were assessed by right heart catheterization. In seven patients with iPAH, iloprost plasma levels were measured. The two iloprost doses caused decreases from baseline in pulmonary vascular resistance (PVR; 2.5 [Formula: see text]g: -14.7%; 5.0 [Formula: see text]g: -15.6%) and mean pulmonary arterial pressure (mPAP; 2.5 [Formula: see text]g: -11.0%; 5.0 [Formula: see text]g: -10.1%) while cardiac index (CI) increased (2.5 [Formula: see text]g: +6.5%; 5.0 [Formula: see text]g: +6.4%). The subset with iPAH also showed decreases from baseline in PVR and mPAP and an increase in CI. Peak iloprost plasma levels showed no significant difference after inhalation of 2.5 [Formula: see text]g or 5.0 [Formula: see text]g iloprost (95.5 pg/mL vs. 73.0 pg/mL; P = 0.06). In summary, nebulized iloprost delivered via the I-neb AAD system reduced mPAP and PVR and increased CI from baseline in a heterogeneous group of patients with PH and in the subset with iPAH. In patients with iPAH, inhalation of 2.5 [Formula: see text]g or 5.0 [Formula: see text]g iloprost resulted in broadly similar peak iloprost plasma levels.
Free Keywords:I-neb Adaptive Aerosol Delivery system; inhaled iloprost; pulmonary arterial hypertension
External Publication Status:published
Document Type:Article
Communicated by:n.n.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Department of Pneumology, Kerckhoff Heart and Thoracic Center, Bad Nauheim, Germany ; Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center, Germany, and German Center for Lung Research ; Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center, Germany, and German Center for Lung Research ; Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center, Germany, and German Center for Lung Research. Department of Pneumology, Asklepios Hospital, Munich-Gauting, Germany, and German Center for Lung Research.
Identifiers:ISSN:2045-8932 (Print) 2045-8932 (Linking) %R 10.1086/679722
URL:http://www.ncbi.nlm.nih.gov/pubmed/25992279
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.